Crossmark

Response to Comment on: “Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”

Crossref DOI link: https://doi.org/10.1007/s40261-022-01244-5

Published Online: 2023-01-12

Published Print: 2023-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Durga, Devarapalli Ranjani

Mounika, Nadella

Mudimala, Pravallika

Adela, Ramu https://orcid.org/0000-0003-0909-2557
License Information

Text and Data Mining valid from 2023-01-12

Version of Record valid from 2023-01-12
More Information

Article History

Accepted: 22 December 2022

First Online: 12 January 2023

Declarations

:

: This research study was funded by the Institutional Core Grant, National Institute of Pharmaceutical Education and Research-Guwahati, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India.

: Devarapalli Ranjani Durga, Nadella Mounika, Pravallika Mudimala, and Ramu Adela have no conflicts of interest that are directly relevant to the content of this response.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: DRD, NM, PM, and RA conceptualized and prepared the response. All the authors read and approved the final manuscript.

Document is current

Any future updates will be listed below